GMAB GENMAB A/S IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1434265
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY19.2%
TTM net income YoY-15.0%
TTM EPS YoY-12.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin93.6%
Operating margin28.6%
Net margin25.9%
FCF margin30.9%
EBITDA margin—
Returns
ROE17.5%
ROA10.0%
ROIC (approx.)12.9%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets54.6%
Debt / equity0.90x
Current ratio2.02x
Interest coverage3.96x
Cash quality & payout
Operating cash flow / net income1.23x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.72B | $3.12B |
| Cost of revenue | $238.00M | $143.00M |
| Gross profit | $3.48B | $2.98B |
| R&D expense | $1.61B | $1.41B |
| SG&A expense | $626.00M | $549.00M |
| Operating income | $1.06B | $972.00M |
| Interest expense | $269.00M | $291.00M |
| Pretax income | $1.20B | $1.33B |
| Income tax | $241.00M | $193.00M |
| Net income | $963.00M | $1.13B |
| EPS (basic) | 15.50 | 17.66 |
| EPS (diluted) | 15.37 | 17.53 |
| Weighted avg. shares (diluted) | 62.69M | 64.66M |
| Balance sheet | ||
| Cash & equivalents | $1.72B | $1.38B |
| Receivables | $1.11B | $923.00M |
| Inventory | $18.00M | $9.00M |
| Current assets | $2.88B | $3.90B |
| PP&E, netmay include right-of-use assets (IFRS) | $153.00M | $137.00M |
| Goodwill | $355.00M | $355.00M |
| Intangibles | $9.12B | $1.73B |
| Total assets | $12.87B | $6.41B |
| Current liabilities | $1.43B | $744.00M |
| Short-term debt | $273.00M | $0 |
| Long-term debt | $5.00B | $0 |
| Total debt | $5.27B | $0 |
| Total liabilities | $7.03B | $1.28B |
| Shareholders' equity | $5.85B | $5.14B |
| Net debt | $3.56B | -$1.38B |
| Shares outstanding | 64.24M | 66.19M |
| Cash flow statement | ||
| Operating cash flow | $1.19B | $1.13B |
| Capital expenditure | $37.00M | $27.00M |
| Free cash flow | $1.15B | $1.10B |
| Investing cash flow | -$5.64B | -$1.45B |
| Financing cash flow | $4.79B | -$566.00M |
| Stock-based compensation | $128.00M | $105.00M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.